These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39245044)

  • 1. Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib.
    Hsiao KY; Chen HP; Rau KM; Liu KW; Shia BC; Chang WS; Liang HY; Hsieh MC
    Oncologist; 2024 Dec; 29(12):e1669-e1679. PubMed ID: 39245044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.
    Tseng KY; Yang MY; Chen WS; Jiang JK; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Yang YW; Lin YZ; Chang CY; Teng HW
    Int J Colorectal Dis; 2024 Dec; 39(1):195. PubMed ID: 39630293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.
    Li B; Yang W; Liu N; Bi D; Yang T; Wu G; Sun Y
    Br J Cancer; 2024 Dec; 131(11):1775-1780. PubMed ID: 39448860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Élez E; Wyrwicz L; Stroyakovskiy D; Liposits G; Bondarenko I; Modest DP; Amellal N; Tabernero J;
    Future Oncol; 2024; 20(36):2823-2832. PubMed ID: 38953855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar.
    Fakih M; Prager GW; Tabernero J; Amellal N; Calleja E; Taieb J
    ESMO Open; 2024 Nov; 9(11):103931. PubMed ID: 39395264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis.
    Azeredo-da-Silva ALF; de Jesus VHF; Agirrezabal I; Brennan VK; Carion PL; Amoury N; Vetromilla BM; Zanotto BS; Shergill S; Ziegelmann PK
    Adv Ther; 2024 Apr; 41(4):1606-1620. PubMed ID: 38407790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
    Shitara K; George B; Taieb J; Sundar R; Fakih MG; Makris L; Benhadji KA; Ghidini M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9361-9374. PubMed ID: 37213030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.
    Ma LX; Titmuss E; Loree JM; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Tu D; O'Callaghan C; Chen EX
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39631846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer.
    Huang LZ; Chen YQ; Gu HY; Chen Y
    Front Public Health; 2024; 12():1465898. PubMed ID: 39606076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial.
    Xiao A; Li X; Wang C; Ye J; Fakih M
    Eur J Cancer; 2024 Dec; 213():115111. PubMed ID: 39504677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Haggstrom L; Chan WY; Nagrial A; Chantrill LA; Sim HW; Yip D; Chin V
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD011044. PubMed ID: 39635901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation.
    Dias J; Tharmanathan P; Arundel C; Welch C; Wu Q; Leighton P; Armaou M; Corbacho B; Johnson N; James S; Cooke J; Bainbridge C; Craigen M; Warwick D; Brady S; Flett L; Jones J; Knowlson C; Watson M; Keding A; Hewitt C; Torgerson D
    Health Technol Assess; 2024 Dec; 28(78):1-262. PubMed ID: 39644138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer.
    Fumet JD; Roussot N; Bertaut A; Limagne E; Thibaudin M; Hervieu A; Zanetta S; Borg C; Senellart H; Pernot S; Thuillier F; Carnot A; Mineur L; Chibaudel B; Touchefeu Y; Martin-Babau J; Jary M; Labourey JL; Rederstorff E; Lepage C; Ghiringhelli F
    Future Oncol; 2024; 20(38):3077-3085. PubMed ID: 39530624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
    Wang Q; Yu J; Sun X; Li J; Cao S; Han Y; Wang H; Yang Z; Li J; Hu C; Zhang Y; Jin L
    Crit Rev Oncol Hematol; 2024 Dec; 204():104522. PubMed ID: 39332750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study.
    Xu D; Zeng S; Qiu W; Wang G; Qin Z; Liu Y; Zhou S; Zhang Z; Chang W; Feng Q; Xu J
    ESMO Open; 2024 Nov; 9(11):103702. PubMed ID: 39395266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.